secwatch.observer — SEC 8-K summary
======================================

Issuer:     TFF Pharmaceuticals, Inc. (—)
CIK:        0001733413
Form:       8-K
Filed at:   2023-04-06T23:59:59+00:00
Accession:  0001213900-23-027969
Event type: other
Sentiment:  neutral
Materiality: 0.20
Item codes: 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TFF Pharmaceuticals amends bylaws to adopt universal proxy rules and other governance changes
--------------------------------------------------------------------------------

- Board approved First Amended and Restated Bylaws on March 31, 2023, effective immediately.
- Section 2.14 adopts universal proxy provisions under Rule 14a-19 of the Exchange Act.
- Section 2.12 permits stockholder action by majority written consent unless prohibited by charter.
- Section 3.9 allows removal of directors with or without cause by majority vote of shares.
- Other revisions reflect recent changes in Delaware General Corporation Law; no material impact on prior disclosures.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1733413/000121390023027969/0001213900-23-027969-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1733413/000121390023027969/ea176605-8k_tffpharma.htm
  HTML page:      https://secwatch.observer/filing/0001213900-23-027969

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer